KEAP1 and hepatocellular carcinoma: The finding that the Nrf 2-Keap1 pathway is activated in very early and small preneoplastic foci and that its activation persists only in those nodules that are considered precursors of HCC in the R-H model [30] makes Nrf 2 an interesting and promising therapeutic target in HCC therapy and suggests its potential prognostic use for the identification of progressive lesions in human HCC development.